GP(33-41) TFA

GP(33-41) TFA, a 9-amino-acid (aa) peptide, represents the optimal sequence of the lymphocytic choriomeningitis virus GP1 epitope, effectively upregulating H-2D b molecules on the RMA-S (Db Kb) cell surface with a SC 50 value of 344 nM [1].

Dynorphin B (1-13), a 13 amino acid, is an extraordinarily potent opioid peptide.

GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM. GP33-41 Epitopeis a strong agonist of CD8 T cells

IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].

Insulin-like Growth Factor I (24-41) TFA, a fragment comprising amino acids 24 to 41 of the full IGF-I TFA molecule, is a variant of IGF-I TFA, which itself is a 70 amino acid polypeptide hormone. This hormone serves as a trophic factor beneficial for both neurons and glial cells, playing a significant role in mediating the effects of growth hormone (GH) on systemic growth. Additionally, IGF-I TFA exhibits anabolic, antioxidant, anti-inflammatory, and cytoprotective properties. The specific fragment IGF-I (24-41) TFA is involved in regulating somatic growth as well as behavioral development [1] [2] [3].

Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.

α-Helical CRF (9-41) is a synthetic peptide antagonist that targets corticotropin-releasing factor (CRF), effectively inhibiting CRF-induced adrenocorticotropic hormone (ACTH) release both in vitro, with isolated rat anterior pituitary cells at concentrations of 0.5 to 5 µM, and in vivo, in non-anesthetized, intact rats at doses ranging from 0.02 to 0.6 µmol/kg. Moreover, it prevents stress-induced ACTH release at a dose of 0.6 µmol/kg in rats and demonstrates the ability to enhance social interaction times in a rat model addressing nicotine-induced conditioned anxiety, in addition to decreasing binge-like ethanol consumption in mice.

LCMV gp33-41 (TFA), an 11-amino-acid carboxyl-extended peptide, comprises a lymphocytic choriomeningitis virus sequence that is presented by MHC class I H-2Db molecules to cytotoxic T lymphocytes [1].

IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).IGF-I (24-41) (TFA) is amino acids 24 to 41 fragment of Insulin-like Growth

Secretin (33-59), rat (TFA), a 27-amino acid peptide, targets the secretin receptor to increase the release of bicarbonate, enzymes, and potassium (K+) from the pancreas [1] [2].

OXA(17-33) TFA is a potent, selective agonist for the orexin-1 receptor (OX1), demonstrating about 23-fold higher affinity for OX1 (EC50 = 8.29 nM) compared to the orexin-2 receptor (OX2) (187 nM) [1].

α-Helical CRF(9-41) TFA acts as a competitive antagonist for the CRF2 receptor, possessing a binding constant (K B) of approximately 100 nM. Additionally, it serves as a partial agonist for the CRF1 receptor, exhibiting a half-maximal effective concentration (EC 50) of 140 nM [1] [2].

hFSH-β-(33-53) TFA, a thiol-containing peptide representing the second follicle-stimulating hormone receptor (FSHR) binding domain, acts as an FSHR antagonist. It prevents FSH from binding to its receptor and partially promotes estradiol synthesis in Sertoli cells [1] [2] [3].

Lactoferrin (17-41) TFA (146897-68-9 free base) is amino acids 17 to 41 fragment of lactoferrin, known as lactoferricin B. Lactoferrin (17-41) TFA (146897-68-9 free base) shows anti-fungal properties in combination of other anti-fungal agents.Candida Albicans is one of the targets of the lactoferricin B.

CRF(6-33)(human) TFA acts as a competitive inhibitor of the Corticotropin-Releasing Factor Binding Protein (CRF-BP), selectively interacting with CRF-BP without affecting post-synaptic Corticotropin-Releasing Factor receptors. This compound demonstrates an anti-obesity effect, as evidenced by studies [1] [2].

IGF-I (30-41) (TFA) is a fragment consisting of amino acids 30 to 41 from Insulin-like Growth Factor I (IGF-I), a compound responsible in part for systemic GH (Growth Hormone) activities. It exhibits an array of properties including anabolic, antioxidant, anti-inflammatory, and cytoprotective actions [1].

Amyloid β-Protein (33-42) TFA, a fragment encompassing residues 33-42 of the β-amyloid protein, mitigates the toxicity induced by Aβ42 [1].

pBD-1 TFA is an endogenous and constitutively expressed antimicrobial peptide (AMP) from porcine tissues, has antimicrobial activities and contributes to mucosal and systemic host defenses in pigs.

Gp100 (25-33), human TFA is a 25-33 amino acid fragment of human melanoma antigen.Gp100 (25-33), human TFA is a 9-amino acid (AA) epitopes restricted by h-2db and recognized by T cells.

Secretin (33-59), rat (TFA) is a 27-aa peptide, which acts on secretin receptor, and enhances the secretion of bicarbonate, enzymes, and K+ from the pancreas[1][2].